替诺福韦灌洗液作为接受性肛交的HIV暴露前预防:安全性、可接受性、药代动力学和药效学(DREAM 01)
在21名HIV阴性男男性行为者中研究三种替诺福韦直肠灌洗液(220mg等渗产品A、660mg等渗产品B、660mg低渗产品C),评估安全性、可接受性、药代动力学和药效学。所有灌洗液耐受性高且无毒性,结肠组织替诺福韦二磷酸浓度超过口服TDF目标浓度,离体HIV攻击显示浓度-效应关系,最大效应1.9 log10。作者认为替诺福韦灌洗液可能提供单次、按需、行为一致的PrEP选择,值得继续开发。
要点
- 三种替诺福韦灌洗液可接受性高且无毒性。
- 结肠组织替诺福韦二磷酸浓度从1小时至给药后3-7天超过目标浓度。
- 单次产品C后6-7天,MMC替诺福韦二磷酸超过口服TDF 300mg按需2-1-1方案稳态预期浓度。
核心结论
- 所有3种替诺福韦灌洗液达到的组织替诺福韦二磷酸浓度和结直肠抗病毒效应超过口服TDF,且全身替诺福韦暴露更低。
- 替诺福韦灌洗液可能提供单次、按需、行为一致的PrEP选择,值得继续开发。
研究设计与样本
- 在21名HIV阴性男男性行为者中研究三种替诺福韦直肠灌洗液:220mg等渗产品A、660mg等渗产品B和660mg低渗产品C。
- 采样血液和结直肠组织以评估安全性、可接受性、药代动力学和药效学。
主要发现
- 灌洗液可接受性高且无毒性。
- 所有产品的中位血浆替诺福韦峰值浓度均数倍低于口服富马酸替诺福韦二吡呋酯(TDF)相关的谷浓度。
- 中位结肠组织黏膜单核细胞(MMC)替诺福韦二磷酸浓度从1小时至给药后3至7天超过目标浓度。
- 单次产品C给药后6-7天,MMC替诺福韦二磷酸超过口服TDF 300mg按需2-1-1方案稳态预期浓度。
- 与用药前基线相比,离体结肠组织HIV攻击后的HIV复制显示浓度-效应关系,最大效应为1.9 log10。
临床怎么用
- 作者认为替诺福韦灌洗液可能提供单次、按需、行为一致的PrEP选择,并值得继续开发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite highly effective HIV preexposure prophylaxis (PrEP) options, no options provide on-demand, nonsystemic, behaviorally congruent PrEP that many desire. A tenofovir-medicated rectal douche before receptive anal intercourse may provide this option. METHODS: Three tenofovir rectal douches-220 mg iso-osmolar product A, 660 mg iso-osmolar product B, and 660 mg hypo-osmolar product C-were studied in 21 HIV-negative men who have sex with men. We sampled blood and colorectal tissue to assess safety, acceptability, pharmacokinetics, and pharmacodynamics. RESULTS: The douches had high acceptability without toxicity. Median plasma tenofovir peak concentrations for all products were several-fold below trough concentrations associated with oral tenofovir disoproxil fumarate (TDF). Median colon tissue mucosal mononuclear cell (MMC) tenofovir-diphosphate concentrations exceeded target concentrations from 1 hour through 3 to 7 days after dosing. For 6-7 days after a single product C dose, MMC tenofovir-diphosphate exceeded concentrations expected with steady-state oral TDF 300 mg on-demand 2-1-1 dosing. Compared to predrug baseline, HIV replication after ex vivo colon tissue HIV challenge demonstrated a concentration-response relationship with 1.9 log10 maximal effect. CONCLUSIONS: All 3 tenofovir douches achieved tissue tenofovir-diphosphate concentrations and colorectal antiviral effect exceeding oral TDF and with lower systemic tenofovir. Tenofovir douches may provide a single-dose, on-demand, behaviorally congruent PrEP option, and warrant continued development. Clinical Trials Registration . NCT02750540.
引用
- Weld ED, McGowan I, Anton P, et al. Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01). J Infect Dis. 2024. PMID: 38019657. doi:10.1093/infdis/jiad535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。